Absynth Biologics

Absynth is developing vaccines and antibodies to prevent and treat bacterial infections with a distinctive technology platform for identifying proprietary antigens that harness the immune system more effectively than other antigens, to stimulate a host protective response. Antimicrobial resistance constitutes a serious danger to public health, which has been acknowledged by the USA Centers for Diseases Control & Prevention and the European Centre for Disease Prevention and Control. Bacterial vaccines have the potential to reduce community reliance on antibiotics and there is evidence that vaccines can contribute to decreased antibiotic usage. 

Absynth has used its technology platform to establish a vaccine pipeline targeting pathogens for substantial markets, in which no marketed vaccines exist. The most advanced vaccine programme targets Staphylococcus aureus, while pipeline vaccine programmes target Clostridium difficile and Streptococcus pyogenes. The Company also has a S. aureus antibody programme in preclinical research. The Company’s approach has the potential to overcome previous limitations through its novel antigens, as well as its innovative approach to using in vivo models and correlates of infection for candidate optimization and selection. Six patent families are filed from which eleven patents have granted.

Organisation type
Keywords
Vaccines, anti-infectives, anti-bacterials, anti-infective antibodies
Membership affiliation
Dr Fiona Marston
Dr Fiona Marston
Chief Executive 
Dr Anthony Upton
Head of Development 

Appleyard Lees

Appleyard Lees is a highly respected and leading firm of European Patent and Trade Mark Attorneys.

They have an experienced life science and chemical team and an enviable reputation of working with some of the most innovative organisations in the UK and around the world.  Acting for a range of clients, including well-known multinational corporations, Universities and SMEs, they have earned a reputation for not only handling complex technical subject matter, but also providing clear and strategic advice.

Appleyard Lees have offices throughout the UK and also in Munich and The Hague.  They are listed in Chambers UK, the Legal500 and Managing IP ‘IP Stars’.

Membership affiliation
Keywords
patent attorney,trade marks
Organisation type
Mr Simon Bradbury
Mr Simon Bradbury
Patent Attorney & Head of Life Sciences 

Atlantic Healthcare plc

Atlantic is an emerging UK biopharmaceutical company that in-licenses or acquires on a global or major regional basis niche late stage clinical development or heritage marketed products that will be prescribed by specialist hospital physicians.  Atlantic is seeking ex-US licensees for Alicaforsen, its Phase 3 ready anti-inflammatory antisense oligonucleotide indicated for pouchitis (orphan disease) and for active distal colitis.

Website:
atlantichc.com
Organisation type
Membership affiliation
Mr Simon Kerr
Mr Simon Kerr
Director of Business Development 

Autifony Therapeutics Ltd

Autifony Therapeutics is developing pharmaceutical treatments for hearing disorders, which affect a significant proportion of the population. Autifony‘s approach is focused on Kv3 potassium channel modulation, a novel mechanism of action. These ion channels regulate neuronal activity within the auditory system, and our new drugs aim to treat age related hearing loss and tinnitus. The lead programme has completed Phase I clinical trials and is about to start two Phase IIa studies – for age related hearing loss in the US, and for tinnitus in the UK (supported by funding from the Technology Strategy Board).

Given Autifony’s focus on modulation of Kv3 channels, which have also been implicated in other neurological and psychiatric disorders, there are opportunities for Autifony to investigate these other indications with compounds with different profiles. Autifony was awarded Technology Strategy Board funding to progress the development of a candidate drug for the treatment of schizophrenia, working together with academic collaborators at the Universities of Manchester and Newcastle.

Autifony Therapeutics Limited was formed in 2011 as a spin-out from GSK. The company is privately funded by leading venture capital investors SV Life Sciences, Imperial Innovations and Pfizer Venture Investments. Autifony’s head office is at the Imperial College Incubator in London, and has a subsidiary with medicinal chemistry and biology labs based in Verona, Italy.

Website:
www.autifony.com
Membership affiliation
Keywords
hearing, tinnitus, schizophrenia, CNS, drug discovery, drug development
Organisation type
Dr Barbara Domayne-Hayman
Chief Business Officer 

Bionow

Bionow is the life-sciences membership organisation for the North of England and supports business growth, competitiveness and innovation within the biomedical and life science sectors. Bionow’s membership offering focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses.

Website:
www.bionow.co.uk
Membership affiliation
Organisation type
Miss Amy Wright
Business Development Associate 

BioPartner UK

BioPartner UK is an independent UK trade organisation, working with government and private agencies to promote UK expertise and provide practical support for those trading overseas.

BioPartner is your point-of-contact for the UK delegation at Bio-Europe 2014.

Organisation type
Keywords
international, business support, trade, missions, events
Membership affiliation

Cambridge Bioscience

Cambridge Bioscience is a well established, leading European distributor of life science products bringing new and exciting technologies to researchers. Working with over forty specialist suppliers around the world, we offer an innovative, extensive and diverse range of over 450,000 products, services and instruments supporting research in the areas of drug discovery, regenerative medicine, cell culture and much more.

The products and services Cambridge Bioscience offers includes:
·         Ion Channel, GPCR & Kinase Profiling Services
·         Primary screening  & Secondary Drug Profiling Services
·         Cardiac Safety Assessment
·         Ion Channel & GPCR Cell Lines
·         Human Tissues, TMAs & Biofluids
·         Primary Cells & Cell Culture Technologies

To find out more, please meet us at the event or contact us using the details below
Cambridge Bioscience
Munro House
Trafalgar Way
Bar Hill
Cambridge 
United Kingdom
CB23 8SQ

Tel: +44 (0)1223 316 855
Fax: +44 (0)1954 781 323
Email: support@bioscience.co.uk
Website: www.bioscience.co.uk

Organisation type
Keywords
distributor
Membership affiliation
Dr Vashu Pamnani
Senior Business Manager 

Canbex Therapeutics

Website:
www.canbex.co.uk
Organisation type
Keywords
drug discovery,neuroscience,therapeutics
Membership affiliation
Dr Keith Powell
Chairman 
Dr Jesse Schulman
CEO 

Centre for Pharmaceutical Engineering Science

The Centre for Pharmaceutical Engineering (CPES) at the University of Bradford combines expertise in pharmaceutics, engineering and solid state chemistry to provide innovative and differentiated contract research offerings and novel technologies to the pharmaceutical industry.

The Centre is developing IP for technologies in the areas of:

  • Effervescent formulations
  • Abuse Resistant Extended Release systems
  • Novel Microneedles
  • Novel Micronisation technology for inhaled products
  • Solvent Free Extrusion processing-co-crystals, stable metastable polymorphs

We are seeking pharmaceutical partners to develop products with our technologies.

We are experts in preclinical formulation development covering:

Formulation of poorly soluble drugs-amorphous forms, nanoparticles, co-crystals, micelles, liposomes and SCF crystallization.

Processes for amorphous forms- Hot melt extrusion, spray drying, injection and micro moulding.

Transdermal drug delivery systems- topical formulation, patches, Lypotropic Liquid Crystal systems, microneedles and Franz cell analysis.

Inhaled formulations - conventional and novel micronisation techniques, full formulation development and analytical testing service for DPI, pMDI and nebulised systems.

Developing sustained and controlled release solid dosage formulation technologies.

Preformulation analysis- We offer a range of analytical techniques and expertise to compliment pharmaceutical development including uHPLC, LCMSMS, SEM, XRD, USP4 Dissolution services, Surface Energy Analysis, particle sizing, DVS, thermal analysis, Raman microscopy.

CPES offers industrial partners excellent academic expertise, a proven problem solving approach and world-class facilities with an excellent project delivery record.

Organisation type
Keywords
academic,centre,university
Membership affiliation
Dr Jason Jones
Commercial Manager 

Clinical Network Services (UK) Ltd

Clinical Network Services (CNS) is an Australian, New Zealand and UK based service group, offering full and integrated drug development consultancy to small – medium sized Biotech companies from inception through to end of phase II clinical trial programs. CNS offers a unique service that brings together BioDesk; an intelligent product development and regulatory planning service, with our highly experienced regional clinical operations and data management teams.

BioDesk is a team of in-house scientists and commercial drug development experts, who work closely with our clients from the earliest of planning stages. Together they create and manage Drug Development Plans, including all stages of pre-clinical/CMC programs that embrace global regulatory strategies whilst leveraging our unique regional advantage.

Australia and New Zealand have an outstanding product development timeline advantage due to our access to a pragmatic regulatory environment that makes it possible to add value to the global regulatory dossier and enter the clinic quickly, without the need for prior approval from another regulatory agency. Our clients have often established initial proof-of-concept quickly, and have enjoyed a time(cost) saving when compared to the more resource-intensive strategy of applying for an IND or CTA.

CNS has worked with clients whose cumulative acquisition price exceeds US$16.5billion; many of these clients initially fast-tracked their programs by running their phase 1 & 2 studies in Australia and New Zealand.

Further information on CNS can be found at www.clinical.net.au

Organisation type
Keywords
product development,regulatory,consultancy
Membership affiliation
Mr Paul Cronin
Director, Business Development 
Mr Russell Neal
Director